Age- and sex-specific incidence of XXXX by immunophenotype in the Nordic countries.

@entity1 @entity981 @entity3052 @entity1778 @entity11511
BACKGROUND: Studies from various countries have found an increasing incidence of @entity1778 in recent decades. To characterize time trends in the age- and sex-specific incidence of childhood @entity3052 during the last 20 years in the Nordic countries, we analyzed a large set of population-based data from the Nordic Society of Paediatric Haematology and Oncology (NOPHO) in their @entity3052 database covering a population of approximately 5 million @entity1 aged 0-14 years. METHODS: Temporal trends in @entity3052 and @entity981 incidence rates overall and for @entity981 immunophenotypes and for specific age groups were analyzed by Poisson regression adjusting for age, sex, and country. All statistical tests were two-sided. RESULTS: We identified 1595 @entity1 and 1859 @entity1 diagnosed with @entity981 between January 1, 1982, and December 31, 2001, and 260 @entity1 and 224 @entity1 diagnosed with de novo @entity3052 between January 1, 1985, and December 31, 2001. No statistically significant change was seen in the overall incidence rate for @entity981 during the 20-year study (annual change = 0.22%, 95% confidence interval [CI] = -0.36% to 0.80%). The incidence rate of B-precursor @entity981 remained unchanged (annual change = 0.30%, 95% CI = -0.57% to 1.18%) from January 1, 1986, through December 31, 2001. A somewhat lower incidence in the first years of the study period indicated an early increasing incidence of B-precursor @entity981 that corresponded to a simultaneous decreasing incidence of unclassified @entity981 . Incidences of @entity11511 (annual change = 1.55%, 95% CI = -1.14% to 4.31%) and @entity3052 (annual change = 0.58%, 95% CI = -1.24% to 2.44%) were stable during the study period. CONCLUSION: Incidences of @entity3052 overall, @entity981 overall, and specific @entity981 immunophenotypes have been stable in the Nordic countries over the past two decades.
